These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 36575213)
1. Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models. Kamitani N; Nakamae I; Yoneda-Kato N; Kato JY; Sho M Sci Rep; 2022 Dec; 12(1):22419. PubMed ID: 36575213 [TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963 [TBL] [Abstract][Full Text] [Related]
3. Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. Prasad S; Yadav VR; Sung B; Gupta SC; Tyagi AK; Aggarwal BB Oncotarget; 2016 Mar; 7(11):13182-96. PubMed ID: 26909608 [TBL] [Abstract][Full Text] [Related]
5. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Wang X; McKernan R; Kim KH; Alvero AB; Whiting A; Thompson JA; Mor G; Saif MW; Husband AJ; Brown DM; Tytler EM Anticancer Drugs; 2011 Sep; 22(8):719-31. PubMed ID: 21666438 [TBL] [Abstract][Full Text] [Related]
6. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918 [TBL] [Abstract][Full Text] [Related]
8. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869 [TBL] [Abstract][Full Text] [Related]
9. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081 [TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357 [TBL] [Abstract][Full Text] [Related]
11. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Luo D; Digiovanni MG; Wei R; Lacomb JF; Williams JL; Rigas B; Mackenzie GG Carcinogenesis; 2020 Jul; 41(7):927-939. PubMed ID: 31584613 [TBL] [Abstract][Full Text] [Related]
12. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814 [TBL] [Abstract][Full Text] [Related]
13. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel. Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974 [TBL] [Abstract][Full Text] [Related]
15. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046 [TBL] [Abstract][Full Text] [Related]
16. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821 [TBL] [Abstract][Full Text] [Related]
17. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer. Zhou B; Zhang J; Chen G; You L; Zhang TP; Zhao YP Cancer Lett; 2013 Feb; 329(1):118-24. PubMed ID: 23142291 [TBL] [Abstract][Full Text] [Related]
18. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Zhang GN; Liang Y; Zhou LJ; Chen SP; Chen G; Zhang TP; Kang T; Zhao YP Cancer Lett; 2011 Dec; 313(2):137-44. PubMed ID: 22030254 [TBL] [Abstract][Full Text] [Related]
19. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656 [TBL] [Abstract][Full Text] [Related]
20. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]